Increased Antitumor Activity in Combined Treatment TS-1 and Docetaxel
- 1 July 2005
- journal article
- Published by S. Karger AG in Oncology
- Vol. 68 (2-3) , 130-137
- https://doi.org/10.1159/000086767
Abstract
As TS-1 and docetaxel (TXT) have different mechanisms of antitumor activity, the combination therapy is expected to have a higher response. Human gastric cancer xenografts SC-2, St-40, and SC-4 inoculated into nude rats were treated with TS-1 alone (TS-1 12 mg/kg/day, day 1-14), TXT alone (TXT 2 mg/kg/day, day 1 or day 8), and combination of both drugs. TS-1 alone showed antitumor activity against three tumors (growth inhibition rate (IR): SC-2 (38.6 and 40.5%), St-40 (54.5%), SC-4 (55.1%)). TXT was effective with minimal toxicity, especially on day 1 of administration (IR at day 1 administration: SC-2 (51.7%), St-40 (42.1%), SC-4 (46.3%)). In the combined TS-1 and TXT group, antitumor activity increased at day 1 and at day 8 TXT administration (IR at day 1 administration: SC-2 (68.4%), St-40 (72.5%), SC-4 (76.0%)). Weight loss of TS-1 and day 1 TXT administration was the same as that of TS-1 alone. TS-1 and TXT showed no pharmacokinetic interaction. Compared with 5-fluorouracil and cisplatin treatment, combined therapy with TS-1 and TXT showed the same antitumor activity and toxicity. Combined therapy with TS-1 and TXT showed enhanced antitumor activity compared with monotherapy of each drug. The outpatient-based treatment of this combination is worth investigating.Keywords
This publication has 17 references indexed in Scilit:
- Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding studyEuropean Journal Of Cancer, 2000
- Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric CancerOncology, 2000
- Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cellsBiochemical Pharmacology, 1999
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal Of Cancer, 1998
- Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in ratsCancer Chemotherapy and Pharmacology, 1996
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublinesin vitroInvestigational New Drugs, 1994
- Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic methodJournal of Chromatography B: Biomedical Sciences and Applications, 1992
- 5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical StudiesCancer Investigation, 1991
- Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.Proceedings of the National Academy of Sciences, 1986